Associations Between HIV-1 DNA Copy Number, Proviral Transcriptional Activity, and Plasma Viremia in Individuals off or on Suppressive Antiretroviral Therapy

Overview

Journal Virology

Specialty Microbiology

Date 2018 Jun 8

PMID 29879542

Citations 17

Authors

Feiyu Hong

Jana L Jacobs

Evgenia Aga

Anthony R Cillo

Elizabeth Fyne

Dianna L Koontz

Lu Zheng

John W Mellors

Affiliations

Soon will be listed here.

Abstract

The relationships between HIV-1 DNA copy number, proviral transcriptional activity, and residual plasma viremia in individuals off and on ART are not well defined. To address this, we performed a cross-sectional study of 12 viremic donors and 23 ART-treated virologically suppressed (plasma HIV-1 RNA<20 copies/ml) donors. We report a strong association between HIV-1 DNA copy number and HIV-1 transcriptional activity in blood that persists on suppressive ART, but not between transcriptional activity and the levels of persistent viremia on ART. The latter finding contrasts with that in viremic donors and suggests that most HIV transcription in donors on suppressive ART does not result in virion production. This uncoupling of proviral transcription and viremia warrants closer investigation.

Citing Articles

HIV-1 control in vivo is related to the number but not the fraction of infected cells with viral unspliced RNA.

Capoferri A, Wiegand A, Hong F, Jacobs J, Spindler J, Musick A Proc Natl Acad Sci U S A. 2024; 121(36):e2405210121.

PMID: 39190360 PMC: 11388345. DOI: 10.1073/pnas.2405210121.

Evaluation of HIV-1 DNA levels among adolescents living with perinatally acquired HIV-1 in Yaounde, Cameroon: A contribution to paediatric HIV cure research in Sub-Saharan Africa.

Kae A, Santoro M, Duca L, Ambe Chenwi C, Ngoufack Jagni Semengue E, Nka A J Virus Erad. 2024; 10(1):100367.

PMID: 38601701 PMC: 11004643. DOI: 10.1016/j.jve.2024.100367.

Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART.

Gartner K, Dominguez-Rodriguez S, Heaney J, Gkouleli T, Grant P, Dorgham K Front Immunol. 2024; 15:1334236.

PMID: 38444847 PMC: 10912947. DOI: 10.3389/fimmu.2024.1334236.

Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies.

Buck A, Deveau T, Henrich T, Deitchman A Viruses. 2023; 15(5).

PMID: 37243212 PMC: 10222761. DOI: 10.3390/v15051126.

Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice.

Belmonti S, Di Giambenedetto S, Lombardi F Diagnostics (Basel). 2022; 12(1).

PMID: 35054206 PMC: 8774405. DOI: 10.3390/diagnostics12010039.

References

Wiegand A, Spindler J, Hong F, Shao W, Cyktor J, Cillo A . Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART. Proc Natl Acad Sci U S A. 2017; 114(18):E3659-E3668. PMC: 5422779. DOI: 10.1073/pnas.1617961114. View

Imamichi H, Dewar R, Adelsberger J, Rehm C, ODoherty U, Paxinos E . Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. Proc Natl Acad Sci U S A. 2016; 113(31):8783-8. PMC: 4978246. DOI: 10.1073/pnas.1609057113. View

Bruner K, Murray A, Pollack R, Soliman M, Laskey S, Capoferri A . Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med. 2016; 22(9):1043-9. PMC: 5014606. DOI: 10.1038/nm.4156. View

Rasmussen T, Tolstrup M, Brinkmann C, Olesen R, Erikstrup C, Solomon A . Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2015; 1(1):e13-21. DOI: 10.1016/S2352-3018(14)70014-1. View

Furtado M, Callaway D, Phair J, Kunstman K, Stanton J, Macken C . Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999; 340(21):1614-22. DOI: 10.1056/NEJM199905273402102. View

Lassen K, Bailey J, Siliciano R . Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol. 2004; 78(17):9105-14. PMC: 506937. DOI: 10.1128/JVI.78.17.9105-9114.2004. View

Malatinkova E, De Spiegelaere W, Bonczkowski P, Kiselinova M, Vervisch K, Trypsteen W . Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. Elife. 2015; 4:e09115. PMC: 4657623. DOI: 10.7554/eLife.09115. View

Sneller M, Justement J, Gittens K, Petrone M, Clarridge K, Proschan M . A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci Transl Med. 2017; 9(419). PMC: 11059970. DOI: 10.1126/scitranslmed.aan8848. View

Procopio F, Fromentin R, Kulpa D, Brehm J, Bebin A, Strain M . A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine. 2015; 2(8):874-83. PMC: 4563128. DOI: 10.1016/j.ebiom.2015.06.019. View

10.

Laird G, Eisele E, Rabi S, Lai J, Chioma S, Blankson J . Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 2013; 9(5):e1003398. PMC: 3667757. DOI: 10.1371/journal.ppat.1003398. View

11.

Pasternak A, DeMaster L, Kootstra N, Reiss P, ODoherty U, Berkhout B . Minor Contribution of Chimeric Host-HIV Readthrough Transcripts to the Level of HIV Cell-Associated gag RNA. J Virol. 2015; 90(2):1148-51. PMC: 4702708. DOI: 10.1128/JVI.02597-15. View

12.

Archin N, Bateson R, Tripathy M, Crooks A, Yang K, Dahl N . HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis. 2014; 210(5):728-35. PMC: 4148603. DOI: 10.1093/infdis/jiu155. View

13.

Williams J, Hurst J, Stohr W, Robinson N, Brown H, Fisher M . HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014; 3:e03821. PMC: 4199415. DOI: 10.7554/eLife.03821. View

14.

Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna G, Brun S . Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008; 105(10):3879-84. PMC: 2268833. DOI: 10.1073/pnas.0800050105. View

15.

Mexas A, Graf E, Pace M, Yu J, Papasavvas E, Azzoni L . Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS. 2012; 26(18):2295-306. PMC: 4692807. DOI: 10.1097/QAD.0b013e32835a5c2f. View

16.

Bullen C, Laird G, Durand C, Siliciano J, Siliciano R . New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014; 20(4):425-9. PMC: 3981911. DOI: 10.1038/nm.3489. View

17.

Cillo A, Vagratian D, Bedison M, Anderson E, Kearney M, Fyne E . Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. J Clin Microbiol. 2014; 52(11):3944-51. PMC: 4313209. DOI: 10.1128/JCM.02060-14. View

18.

Yukl S, Kaiser P, Kim P, Telwatte S, Joshi S, Vu M . HIV latency in isolated patient CD4 T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med. 2018; 10(430). PMC: 5959841. DOI: 10.1126/scitranslmed.aap9927. View

19.

Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H . Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med. 2007; 13(10):1241-7. DOI: 10.1038/nm1639. View

20.

Koelsch K, Liu L, Haubrich R, May S, Havlir D, Gunthard H . Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis. 2008; 197(3):411-9. DOI: 10.1086/525283. View